Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A dually active anthrax vaccine that confers protection against both bacilli and toxins.

Literature DB >> 12960361

A dually active anthrax vaccine that confers protection against both bacilli and toxins.

Gi-Eun Rhie¹, Michael H Roehrl, Michael Mourez, R John Collier, John J Mekalanos, Julia Y Wang.

Abstract

Systemic anthrax is caused by unimpeded bacillar replication and toxin secretion. We developed a dually active anthrax vaccine (DAAV) that confers simultaneous protection against both bacilli and toxins. DAAV was constructed by conjugating capsular poly-gamma-d-glutamic acid (PGA) to protective antigen (PA), converting the weakly immunogenic PGA to a potent immunogen, and synergistically enhancing the humoral response to PA. PGA-specific antibodies bound to encapsulated bacilli and promoted the killing of bacilli by complement. PA-specific antibodies neutralized toxin activity and protected immunized mice against lethal challenge with anthrax toxin. Thus, DAAV combines both antibacterial and antitoxic components in a single vaccine against anthrax. DAAV introduces a vaccine design that may be widely applicable against infectious diseases and provides additional tools in medicine and biodefense.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2003 PMID： 12960361 PMCID： PMC196904 DOI： 10.1073/pnas.1834478100

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

23 in total

1. Designing a polyvalent inhibitor of anthrax toxin.

Authors: M Mourez; R S Kane; J Mogridge; S Metallo; P Deschatelets; B R Sellman; G M Whitesides; R J Collier
Journal: Nat Biotechnol Date: 2001-10 Impact factor: 54.908

Review 2. Development of an improved vaccine for anthrax.

Authors: Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal: J Clin Invest Date: 2002-07 Impact factor: 14.808

3. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors: B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal: Infect Immun Date: 2001-07 Impact factor: 3.441

4. Biosynthesis and ultrasonic degradation of bacterial poly(gamma-glutamic acid).

Authors: G Pérez-Camero; F Congregado; J J Bou; S Muñoz-Guerra
Journal: Biotechnol Bioeng Date: 1999-04-05 Impact factor: 4.530

Review 5. Anthrax.

Authors: M Mock; A Fouet
Journal: Annu Rev Microbiol Date: 2001 Impact factor: 15.500

6. The capsule and S-layer: two independent and yet compatible macromolecular structures in Bacillus anthracis.

Authors: S Mesnage; E Tosi-Couture; P Gounon; M Mock; A Fouet
Journal: J Bacteriol Date: 1998-01 Impact factor: 3.490

7. Identification of residues lining the anthrax protective antigen channel.

Authors: E L Benson; P D Huynh; A Finkelstein; R J Collier
Journal: Biochemistry Date: 1998-03-17 Impact factor: 3.162

8. Effect of Bacillus anthracis lethal toxin on human peripheral blood mononuclear cells.

Authors: Serguei G Popov; Rafael Villasmil; Jessica Bernardi; Edith Grene; Jennifer Cardwell; Taissia Popova; Aiguo Wu; Darya Alibek; Charles Bailey; Ken Alibek
Journal: FEBS Lett Date: 2002-09-11 Impact factor: 4.124

9. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence.

Authors: S L Welkos; N J Vietri; P H Gibbs
Journal: Microb Pathog Date: 1993-05 Impact factor: 3.738

10. N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis.

Authors: H J Jennings; A Gamian; F E Ashton
Journal: J Exp Med Date: 1987-04-01 Impact factor: 14.307

39 in total

1. Dermatan sulfate interacts with dead cells and regulates CD5(+) B-cell fate: implications for a key role in autoimmunity.

Authors: Julia Y Wang; Jongmin Lee; Ming Yan; Jung-hyun Rho; Michael H A Roehrl
Journal: Am J Pathol Date: 2011-05 Impact factor: 4.307

2. Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule.

Authors: Zhaochun Chen; Rachel Schneerson; Julie Lovchik; C Rick Lyons; Huaying Zhao; Zhongdong Dai; Joanna Kubler-Kielb; Stephen H Leppla; Robert H Purcell
Journal: Proc Natl Acad Sci U S A Date: 2010-12-27 Impact factor: 11.205

3. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax.

Authors: Melissa Drysdale; Sara Heninger; Julie Hutt; Yahua Chen; C Rick Lyons; Theresa M Koehler
Journal: EMBO J Date: 2004-12-16 Impact factor: 11.598

4. Identification of a second collagen-like glycoprotein produced by Bacillus anthracis and demonstration of associated spore-specific sugars.

Authors: Lashanda N Waller; Michael J Stump; Karen F Fox; William M Harley; Alvin Fox; George C Stewart; Mona Shahgholi
Journal: J Bacteriol Date: 2005-07 Impact factor: 3.490

5. Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Authors: Orit Gat; Haim Grosfeld; Naomi Ariel; Itzhak Inbar; Galia Zaide; Yehoshua Broder; Anat Zvi; Theodor Chitlaru; Zeev Altboum; Dana Stein; Sara Cohen; Avigdor Shafferman
Journal: Infect Immun Date: 2006-07 Impact factor: 3.441

6. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.

Authors: Ming Yan; Michael H Roehrl; Emre Basar; Julia Y Wang
Journal: Vaccine Date: 2007-12-26 Impact factor: 3.641

7. Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax.

Authors: Zhaochun Chen; Rachel Schneerson; Julie A Lovchik; Zhongdong Dai; Joanna Kubler-Kielb; Liane Agulto; Stephen H Leppla; Robert H Purcell
Journal: Clin Vaccine Immunol Date: 2015-06-03